Validation of the pulmonary hypertension connection equation for survival prediction in pulmonary arterial hypertension

Chest

Volumn 141, Issue 3, 2012, Pages 642-650

  Thenappan, Thenappan ^a   Glassner, Cherylanne ^a   Gomberg Maitland, Mardi ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACCURACY; ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; HEART HEMODYNAMICS; HEART INDEX; HEART OUTPUT; HUMAN; INTERMETHOD COMPARISON; LUNG ARTERY PRESSURE; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL ANALYSIS; MATHEMATICAL COMPUTING; MEAN ARTERIAL PRESSURE; OVERALL SURVIVAL; PATIENT ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULMONARY HYPERTENSION; RISK ASSESSMENT; SURVIVAL RATE; SURVIVAL TIME;

EID: 84857952439     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.11-0969     Document Type: Article

References (20)

1. Zhang R, Dai LZ, Xie WP, et al. Survival of Chinese patients with pulmonary arterial hypertension in the modern treatment era. Chest. 2011;140(2):301-309.
2. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med. 2006;173(9):1023-1030.
3. Thenappan T, Shah SJ, Rich S, Gomberg-Maitland M. A USA-based registry for pulmonary arterial hypertension: 1982-2006. Eur Respir J. 2007;30(6):1103-1110. (Pubitemid 351194756)
4. Benza RL, Miller DP, Gomberg-Maitland M, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation. 2010;122(2):164-172.
5. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med. 1991;115(5):343-349.
6. McLaughlin VV, Archer SL, Badesch DB, et al ACCF/AHA. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation. 2009;119(16):2250-2294.
7. Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation. 2010;122(2):156-163.
8. Thenappan T, Shah SJ, Rich S, Tian L, Archer SL, Gomberg-Maitland M. Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation. Eur Respir J. 2010;35(5):1079-1087.
9. Humbert M, Sitbon O, Yaïci A, et al French Pulmonary Arterial Hypertension Network. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J. 2010;36(3):549-555.
10. McGoon MD, Krichman A, Farber HW, et al. Design of the REVEAL registry for US patients with pulmonary arterial hypertension. Mayo Clin Proc. 2008;83(8):923-931.
11. Justice AC, Covinsky KE, Berlin JA. Assessing the generalizability of prognostic information. Ann Intern Med. 1999; 130(6):515-524. (Pubitemid 29135805)
12. Bleeker SE, Moll HA, Steyerberg EW, et al. External validation is necessary in prediction research: a clinical example. J Clin Epidemiol. 2003;56(9):826-832. (Pubitemid 37162656)
13. Simonneau G, Barst RJ, Galie N, et al Treprostinil Study Group. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2002;165(6):800-804. (Pubitemid 34229650)
14. Barst RJ, McGoon M, McLaughlin V, et al Beraprost Study Group. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2003;41(12):2119-2125. (Pubitemid 36724255)
15. Barst RJ, Galie N, Naeije R, et al. Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. Eur Respir J. 2006;28(6):1195-1203. (Pubitemid 44883856)
16. Lang I, Gomez-Sanchez M, Kneussl M, et al. Efficacy of longterm subcutaneous treprostinil sodium therapy in pulmonary hypertension. Chest. 2006;129(6):1636-1643. (Pubitemid 43894997)
17. Hiremath J, Thanikachalam S, Parikh K, et al TRUST Study Group. Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial. J Heart Lung Transplant. 2010;29(2):137-149.
18. Gomberg-Maitland M, Michelakis ED. A global pulmonary arterial hypertension registry: is it needed? Is it feasible? Pulmonary vascular disease: the global perspective. Chest. 2010;137(suppl 6):95S-101S.
19. Kawut SM, Taichman DB, Archer-Chicko CL, Palevsky HI, Kimmel SE. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest. 2003;123(2):344-350. (Pubitemid 36269414)
20. Fisher MR, Mathai SC, Champion HC, et al. Clinical differences between idiopathic and scleroderma-related pulmonary hypertension. Arthritis Rheum. 2006;54(9):3043-3050. (Pubitemid 44497786)